Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes
Open Access
- 28 February 2020
- journal article
- research article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine Technology
- Vol. 48 (3) , 191-201
Abstract
Current statistics show there are 3.5 million women in the United States living with breast cancer today, and approximately 330,000 new cases are diagnosed each year. Of these new cases, 81% are identified as invasive cancers (1). About 41,000 women die from breast cancer each year (1). Thankfully survival rates have increased over the years (2); however, an accurate diagnosis and treatment plan remain essential factors for patient survival and longevity. Sometimes breast cancer patients present to their Medical Oncologist with a clinical dilemma on how they should treat their particular breast cancer, especially when standard treatment options fail. Some breast cancer tumors respond to treatment, while others do not. Knowing the type of breast tumor a patient has, its estrogen receptor site status, and how it might respond to therapy is vital information a Medical Oncologist needs to effectively and successfully treat their patients, ultimately improving patient outcomes and overall survival rates for their patients. A potential new Position Emission Tomography (PET) tracer 18F - FES (Fluoroestradiol) (Currently under Federal Drug Administration (FDA) review for approval) (3) may be a valuable tool for Medical Oncologists to use to evaluate the estrogen receptor site status of their patients’ primary tumor and secondary metastatic lesions in a non-invasive manner. Estrogen receptor site imaging is like getting a whole-body biopsy helping to localize all estrogen positive lesions in the body, so an effective treatment plan can be established for each patient. Estrogen receptor site imaging may be beneficial when tumor location is inaccessible or difficult to biopsy. Over the years, Nuclear Medicine has played a crucial role in providing useful information to Medical Oncologists helping to accurately diagnosis and treat their patients. With advances in both camera technology and radiopharmaceutical development, the information Nuclear Medicine has been able to provide Medical Oncologists has only gotten better, allowing Medical Oncologists to more accurately treat and manage their patients.Keywords
This publication has 24 references indexed in Scilit:
- A Molecular Approach to Breast ImagingJournal of Nuclear Medicine, 2014
- Can Fluorine-18 Fluoroestradiol Positron Emission Tomography–Computed Tomography Demonstrate the Heterogeneity of Breast Cancer In Vivo?Clinical Breast Cancer, 2013
- Feasibility and Predictability of Perioperative PET and Estrogen Receptor Ligand in Patients with Invasive Breast CancerJournal of Nuclear Medicine, 2013
- Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor ProgressionJournal of Clinical Oncology, 2012
- Breast Imaging Devices for Nuclear MedicineJournal of Nuclear Medicine Technology, 2012
- PET Imaging of Estrogen Receptors as a Diagnostic Tool for Breast Cancer Patients Presenting with a Clinical DilemmaJournal of Nuclear Medicine, 2012
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast CancerClinical Cancer Research, 2011
- Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance ImagingJournal of Clinical Oncology, 2011
- Breast imaging: A surveyWorld Journal of Clinical Oncology, 2011
- Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-FluoroestradiolJournal of Nuclear Medicine, 2008